Drugs / INO-4212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02464670 | May 2015 → May 2018 | Ebola hemorrhagic fever | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-10-15 | Inovio Pharmaceuticals | Results Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its Ebola vaccine (INO-4212) provided 100% protection following a challenge with a lethal dose of the Ebola virus in a preclinical study. |
| 2016-08-11 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen inovio.com ↗
Inovio is enrolling 125 subjects in a second stage of its phase I trial of INO-4212 after generating positive initial safety and immune response data in the first set of 75 healthy volunteers. |
| 2016-03-30 | Inovio Pharmaceuticals | Results Inovio Ebola Vaccine Generates Robust Immune Responses in Humans inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its fully enrolled phase I study of 75 healthy subjects. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-10-15 | Inovio Pharmaceuticals | Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies inovio.com ↗ |
| 2016-08-11 | Inovio Pharmaceuticals | Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen inovio.com ↗ |
| 2016-03-30 | Inovio Pharmaceuticals | Inovio Ebola Vaccine Generates Robust Immune Responses in Humans inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-4212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02464670 ↗ |
| Modality | Vaccine | “This study will test the safety, tolerability, and immunogenicity of the DNA vaccine, INO-4212 and its components INO-4201 and INO-4202 in healthy volunteers.” NCT02464670 ↗ |
| Route | Intramuscular | “INO-4212 delivered IM followed by Electroporation” NCT02464670 ↗ |